Welcome to our dedicated page for Enzo Biochem news (Ticker: ENZ), a resource for investors and traders seeking the latest updates and insights on Enzo Biochem stock.
Enzo Biochem, Inc. (historically ENZ on the NYSE and later ENZB on OTCQX) generated a steady stream of corporate and financial news as a life sciences company focused on labeling and detection technologies from DNA to whole cell analysis. Its disclosures highlight a portfolio of thousands of products, including antibodies, genomic probes, assays, biochemicals, and proteins that support translational research and drug development in areas such as cell biology, genomics, immunohistochemistry, and small molecule chemistry.
The company’s news flow has included quarterly and annual financial results, where Enzo reported on revenue trends in its Life Sciences division, gross margin performance, operating loss or income, and the impact of cost containment initiatives and product mix. These releases often discussed demand from drug development and cell and gene therapy market segments, as well as the use of non-GAAP measures like Adjusted net loss and Adjusted EBITDA, with reconciliations provided in accompanying tables.
Enzo’s announcements have also covered strategic and corporate actions, such as its exit from the clinical lab business, focus on life science tools, workforce and cost initiatives, and product life cycle management, including removal of non-performing SKUs and new product launches. Governance and corporate updates have included officer appointments, board changes, and shareholder meeting results.
In 2025, the news record shows important capital markets and M&A developments, including NYSE non-compliance notices, a voluntary delisting from the NYSE, transfer of trading to OTCQX, and the subsequent agreement and completion of a merger with Bethpage Parent, Inc., after which Enzo became a wholly owned subsidiary and its shares ceased trading. For readers reviewing ENZ or ENZB news, this page serves as a historical archive of earnings releases, strategic reviews, listing changes, and merger-related communications.
Enzo Biochem has announced its agreement with Labcorp for the sale of its Clinical Laboratory division, part of its strategy to enhance shareholder value. This move follows the company's focused return initiative initiated in 2022. CEO Hamid Erfanian emphasized that the sale will enable Enzo to explore further actions to maximize value and strengthen its position in the life sciences sector. The transaction is contingent on shareholder approval and customary conditions. Enzo's remaining division, Enzo Life Sciences, continues to offer products essential for drug discovery and research, including antibodies and biochemicals.
Enzo Life Sciences reported $18.3 million in revenue for Q1 FY23, a 31% decrease year-over-year, primarily due to a substantial drop in COVID testing revenues. Notably, the Life Sciences division saw a 9% growth in revenue, reflecting strong market potential. The company is progressing in market expansion and new product launches, including the LoopRNA™ product. However, gross margins plummeted to 20% from 42% a year prior, contributing to a net loss of $10.6 million or ($0.22) per share. The company maintains a strong current ratio and minimal debt.
Enzo Biochem, Inc. (NYSE:ENZ) will report its first quarter fiscal 2023 financial results on December 12, 2022, after market close. This will be followed by a live conference call on December 13, 2022, at 8:30 AM ET. The call can be accessed via phone or through a webcast linked on their website. Enzo Biochem focuses on molecular diagnostics, developing technologies that advance healthcare solutions. The company maintains a strong intellectual property portfolio supporting its innovations.
Enzo Biochem (NYSE: ENZ) announced its Annual Shareholders’ Meeting set for January 31, 2023. Shareholders must submit proposals or director nominations by November 18, 2022, to be considered timely. Enzo Biochem is a leader in molecular diagnostics, focusing on developing innovative diagnostic platform technologies that cater to evolving healthcare needs. The company boasts a strong intellectual property portfolio, covering key enabling technologies in the biosciences sector.
Enzo Biochem (NYSE: ENZ) announces the resignation of CFO David Bench, effective November 14, 2022, to pursue a new career opportunity. Patricia Eckert, CPA, has been appointed as interim CFO, leveraging her extensive experience at Enzo and previous roles at Pall Corporation. Eckert aims to support the company's focused return strategy and enhance investor outreach. Enzo, a leader in molecular diagnostics, continues to innovate in healthcare technology.
Enzo Biochem reported FY 2022 revenues of $32.6 million, reflecting an 8% growth. The company launched its AMPIVIEW™ gene expression platform using LoopRNA™ ISH technology, enhancing its oncology position. Despite macroeconomic challenges and reduced COVID-19 testing, Enzo aims for strategic growth, targeting new customer bases and expanding services. FY 2022 net loss was $(18.3) million, compared to $7.9 million profit in 2021. Cash and equivalents stood at $21.6 million, with a strong current ratio of 2.2x.
Enzo Biochem (NYSE:ENZ) will report its fourth quarter 2022 financial results on October 14, 2022, before market open. A live audio webcast and conference call will follow at 8:30 AM ET. The company is a leader in biosciences and diagnostics, focused on developing unique diagnostic technologies and possesses a robust intellectual property portfolio.
Enzo Biochem, Inc. (NYSE: ENZ) has officially launched a new 100,000 square foot laboratory and research facility in Farmingdale, New York. This expansion supports the company’s growth in clinical laboratory services, drug development services, and product innovations. With approximately 500 employees, Enzo plans to further increase job opportunities. The event included discussions on local business growth and featured comments from community leaders. The opening is expected to enhance Enzo’s leadership in life sciences and deepen its commitment to Long Island.
Enzo Biochem, Inc. (NYSE: ENZ) has launched the AMPIVIEW™ RNA gene expression platform, utilizing its innovative LoopRNA™ ISH technology for enhanced detection of biomarkers. This new platform focuses on HPV detection, significantly strengthening Enzo's presence in the oncology sector. The spatial biology market is projected to hit $2.15B by 2030, highlighting growth potential. Enzo's advancements in HPV testing align with its commitment to women's health, with the HPV testing market expected to reach $7.3B by 2028.
Enzo Biochem (NYSE: ENZ) has announced its clinical laboratory will start accepting specimens for monkeypox testing this week. Amidst rising monkeypox cases in the U.S. and globally, the company aims to enhance public health responses. The FDA-cleared PCR-based DNA assay developed by the CDC will be utilized. Enzo is also advancing its technical capabilities to improve collection methods and test turnaround times while ensuring high analytical sensitivity and specificity.